• The major growth factors for cancer biomarkers were increasing usage of biomarkers in cancer treatment in addition to R&D funding for pharma and biotech companies • The distribution channel was smoothly steering growth as Saudi Arabia imports from Europe and conducted tests.

1. Saudi Arabia Tumor
Marker Market
Analysis, 2020
marknteladvisors.com

2. Copyright 2020. Reproduction is forbidden unless authorized. All rights reserved. 2
Document Outline
Table of Content
Market Segmentation, Scope of Work
05
Research Process & Methodology
Primary Research, Secondary Research, Companies Interviewed, Respondent Profile, Research
Methodology, Forecasting
14
Introduction
About Us, Key Questions Answered In This Study
02
Sample Pages
Saudi Arabia Tumor Marker Market Analysis, 2020
22
Commercials 48
Disclaimer 50

3. Copyright 2020. Reproduction is forbidden unless authorized. All rights reserved. 3
Market Segmentation
• Ovarian
• Leukaemia
• Prostate
• Thyroid
• Breast
• Colorectal
• Lung
• Others (Liver)
Saudi Arabia Tumor Marker Market
• Diagnosis
• Screening
• Determine
response to
therapy
By Form
By Class
• Fujirebio
• Randox
• Bio-Rad
• Cepheid
• Roche
• MP Biomedicals
• DiaSorin
• Leica Biosystems
• Biomerieux
By Company
• Cancer Antigen 19-9
• Alpha-fetoprotein
• Beta-2-microglobulin
(B2M)
• Cancer antigen 125
• Prostate-specific Antigen
• Cancer Antigen 15-3 & CA
27-29
• Thyroid Transcription
Factor-1
• Crcinoembryonic antigen
• Others (Bladder Tumor,
Lactate dehydrogenase
(LDH)
By Application
• East
• West
• South
• Central
• North
By Region

4. Copyright 2020. Reproduction is forbidden unless authorized. All rights reserved. 4
Table of Content (1/7)
Historical Year: 2015
Base Year: 2019
Forecast Year: 2025
Table of Content
1. Introduction
1.1. Product Definition
1.2. Research Process
1.3. Glossary
1.4. Market Segmentation
2. Executive Summary
3. Saudi Arabia Healthcare Market Overview
4. Impact of COVID-19 on Saudi Arabia Tumor Marker Market
5. Expert Verbatim- Interview Excerpts of industry experts
6. Saud Arabia Tumor Marker Market Outlook, 2015-2025F
6.1. Market Size & Analysis
6.1.1.Revenues
6.2. Market Share & Analysis
6.2.1.By Application
6.2.1.1. Cancer antigen 19-9
6.2.1.2. Alpha-fetoprotein
6.2.1.3. Beta-2-microglobulin (B2M)
6.2.1.4. Cancer antigen 125
6.2.1.5. Prostate-Specific Antigen
6.2.1.6. Cancer Antigen 15-3 & CA 27-29

5. Copyright 2020. Reproduction is forbidden unless authorized. All rights reserved. 5
Table of Content (2/7)
Historical Year: 2015
Base Year: 2019
Forecast Year: 2025
Table of Content
6.2.1.7. Thyroid Transcription factor-1
6.2.1.8. Crcinoembryonic antigen
6.2.1.9. Others
6.2.2.By Class
6.2.2.1. Diagnosis
6.2.2.2. Screening
6.2.2.3. Determine response to therapy
6.2.3.By Form
6.2.3.1. Ovarian
6.2.3.2. Leukaemia
6.2.3.3. Prostate
6.2.3.4. Thyroid
6.2.3.5. Breast
6.2.3.6. Colorectal
6.2.3.7. Lung
6.2.3.8. Others (Liver)
6.2.4.By Region
6.2.4.1. North
6.2.4.2. West
6.2.4.3. South

6. Copyright 2020. Reproduction is forbidden unless authorized. All rights reserved. 6
Table of Content (3/7)
Historical Year: 2015
Base Year: 2019
Forecast Year: 2025
Table of Content
6.2.4.4. East
6.2.4.5. Central
6.2.5.By Company
6.2.5.1. Market Shares, By Revenue
6.2.5.2. Strategic Factorial Indexing
6.2.5.3. Competitor Placement in MarkNtel Quadrant
6.3. Saudi Arabia Ovarian Tumor Marker Market Outlook, 2015-2025F
6.3.1.Market Size & Analysis
6.3.1.1. By Revenue
6.3.2.Market Share & Analysis
6.3.2.1. By Application
6.3.2.2. By Form
6.3.2.3. By Region
6.4. Saudi Arabia Leukaemia Tumor Marker Market Outlook, 2015-2025F
6.4.1.Market Size & Analysis
6.4.1.1. By Revenue
6.4.2.Market Share & Analysis
6.4.2.1. By Application
6.4.2.2. By Form
6.4.2.3. By Region

7. Copyright 2020. Reproduction is forbidden unless authorized. All rights reserved. 7
Table of Content (4/7)
Historical Year: 2015
Base Year: 2019
Forecast Year: 2025
Table of Content
6.5. Saudi Arabia Prostate Tumor Marker Market Outlook, 2015-2025F
6.5.1.Market Size & Analysis
6.5.1.1. By Revenue
6.5.2.Market Share & Analysis
6.5.2.1. By Application
6.5.2.2. By Form
6.5.2.3. By Region
6.6. Saudi Arabia Thyroid Tumor Marker Market Outlook, 2015-2025F
6.6.1.Market Size & Analysis
6.6.1.1. By Revenue
6.6.2.Market Share & Analysis
6.6.2.1. By Application
6.6.2.2. By Form
6.6.2.3. By Region
6.7. Saudi Arabia Breast Tumor Marker Market Outlook, 2015-2025F
6.7.1.Market Size & Analysis
6.7.1.1. By Revenue
6.7.2.Market Share & Analysis
6.7.2.1. By Application
6.7.2.2. By Form

8. Copyright 2020. Reproduction is forbidden unless authorized. All rights reserved. 8
Table of Content (5/7)
Historical Year: 2015
Base Year: 2019
Forecast Year: 2025
Table of Content
6.7.2.3. By Region
6.8. Saudi Arabia Colorectal Tumor Marker Market Outlook, 2015-2025F
6.8.1.Market Size & Analysis
6.8.1.1. By Revenue
6.8.2.Market Share & Analysis
6.8.2.1. By Application
6.8.2.2. By Form
6.8.2.3. By Region
6.9. Saudi Arabia Lung Tumor Marker Market Outlook, 2015-2025F
6.9.1.Market Size & Analysis
6.9.1.1. By Revenue
6.9.2.Market Share & Analysis
6.9.2.1. By Application
6.9.2.2. By Form
6.9.2.3. By Region
6.10. Saudi Arabia Tumor Marker Market Attractiveness Index
6.10.1. By Application
6.10.2. By Form
6.10.3. By Form
6.10.4. By Region

9. Copyright 2020. Reproduction is forbidden unless authorized. All rights reserved. 9
Table of Content (6/7)
Historical Year: 2015
Base Year: 2019
Forecast Year: 2025
Table of Content
7. Saud Arabia Tumor Marker Market Policies, Regulations, Product Standards
8. Saud Arabia Tumor Marker Market Trends & Insights
9. Saud Arabia Tumor Marker Market Dynamics
9.1. Growth Drivers
9.2. Challenges
9.3. Impact Analysis
10. Saud Arabia Tumor Marker Market Hotspots & Opportunities
11. Saud Arabia Tumor Marker Market Key Strategic Imperatives for Success & Growth
12. Saud Arabia Tumor Marker Market Competition Outlook
12.1. Competition Matrix
12.1.1. Product Portfolio
12.1.2. Research & Development
12.1.3. Strategic Alliances
12.1.4. Strategic Initiatives
12.2. Company Profiles of top companies (Business Description, Product Segments, Business Segments, Financials,
Strategic Alliances/ Partnerships, Future Plans)
12.2.1. Fujirebio
12.2.2. Randox
12.2.3. Bio-Rad
12.2.4. Cepheid
12.2.5. Roche

10. Copyright 2020. Reproduction is forbidden unless authorized. All rights reserved. 10
Table of Content (7/7)
Historical Year: 2015
Base Year: 2019
Forecast Year: 2025
Table of Content
12.2.6. MP Biomedicals
12.2.7. DiaSorin
12.2.8. Leica Biosystems
12.2.9. Biomerieux
13. Disclaimer

11. Copyright 2020. Reproduction is forbidden unless authorized. All rights reserved. 11
Document Outline
Table of Content
Market Segmentation, Scope of Work
05
Research Process & Methodology
Primary Research, Secondary Research, Companies Interviewed, Respondent Profile, Research
Methodology, Forecasting
14
Introduction
About Us, Key Questions Answered In This Study
02
Sample Pages
Saudi Arabia Tumour Marker Market Analysis, 2020
22
Commercials 48
Disclaimer 50

12. Copyright 2020. Reproduction is forbidden unless authorized. All rights reserved.
Saudi Arabia Tumor Marker Overview

13. Copyright 2020. Reproduction is forbidden unless authorized. All rights reserved. 13
Saudi Arabia Tumor Marker Overview
EGFR targeted in-non-small
cell-lung cancer
EGFR targeted in colorectal
cancer
Prostate Cancer
Colorectal cancer
Non small cell-lung
cancer
Breast Cancer
ALK targeted in non-small cell-
lung cancer
HER2-targeted in Breast cancer
Targeted Therapy Biomarkers
• Trastuzumab
• Pertuzumab
• Gefitinib
• Erlotnib
• Certinib
• Criotinib (+MET)
• Cetuximab
• Penitumumab
• HER2
• PR
• ER
• BRCA1
• P53
• KRAS
• BRCA1
• CEA
• EGFR1
• KRAS
• LOH
• BRCA2
• CTC
• PSCA
Source: NCBI
Figure 3: Saudi Arabia Tumor Marker Overview- Types of Biomarkers Used for Targeted Therapy

14. Copyright 2020. Reproduction is forbidden unless authorized. All rights reserved.
Saudi Arabia Impact of COVID-19 on Tumor Marker Market

15. Copyright 2020. Reproduction is forbidden unless authorized. All rights reserved. 15
Covid-19 Impact on Saudi Arabia Tumor Marker Market
Q2 2019 Q3 2019 Q4 2019
By Q2 2019- Q4 2019
Pre Covid-19 Scenario
2020 Q1 2021F
By 2020-2021F
Covid- 19 Impact
Q2
2021F
2022F 2023F 2024F 2025F
By Q2 2021- 2025F
Post Covid-19 Scenario
Pre Covid-19 Impact:
• The major growth factors for cancer biomarkers were
increasing usage of biomarkers in cancer treatment in
addition to R&D funding for pharma and biotech companies
• The distribution channel was smoothly steering growth as
Saudi Arabia imports from Europe and conducted tests.
Figure 4: Saudi Arabia Tumor Marker Market Growth Rate, In Percentage, By Q2 2019- 2025F
Post Covid-19 Scenario
• The novel Covid-19, is expected to affect the cancer tumor
biomarkers market and the cancer patients. This would leave a
negative impact on the tumor marker market.
• The perilous COVID-19 is expected to remain till the next year 2021,
which would negatively impact the supply chain and distribution of
marker kits due to the unprecedented spread of the virus worldwide
and ramp up in the number of cases.

16. Copyright 2020. Reproduction is forbidden unless authorized. All rights reserved.
Saudi Arabia Tumor Marker Market Outlook, 2015-2025F

17. Copyright 2020. Reproduction is forbidden unless authorized. All rights reserved. 17
Saudi Arabia Tumor Marker Market Outlook, By Revenues
Figure XX: Saudi Arabia Tumor Marker Market Revenues (USD Million), 2015 - 2025F
• The total population of Saudi Arabia in 2019 was around 34.14 million. The healthcare infrastructure is constantly developing with the
advancement of technology. The country plans to privatize around 290 hospitals and 2,300 primary health centers by 2030, under the
vision 2030. With the technological advancement and upsurge in the healthcare spending the demand for tumor markers would also
bolster. The accentuating number of cases of different cancer coupled with the aging population in the country is aiding in the growth of
marker for diagnosis and screening which would eventually accelerate the growth of cancer tumor marker in Saudi Arabia.
• In Saudi Arabia, the lung and the breast cancer are the most dominant form of cancer. However, in Saudi Arabia, the International Agency
for Research on Cancer (IARC) estimated that the ASIR for liver cancer was 4.5 per 100,000 population in 2018, and the age-standardized
mortality rate (ASMR) was 4.2 per 100,000 population. Thus, diagnosing and screening is easier with these markers available in the
2015 2016 2017 2018 2019 2020E 2021F 2022F 2023F 2024F 2025F
CAGR
CAGR
Revenue: X% Revenue: X%
Source: MarkNtel Advisors
Figure 5: Saudi Arabia Tumor Marker Market Share, By Revenue (USD Million), 2015-2025F

18. Copyright 2020. Reproduction is forbidden unless authorized. All rights reserved. 18
Saudi Arabia Tumor Marker Market Outlook, By Revenues
2016
2018
2282
1659
1076
841
610 496 454 446 417 405
Breast Colorectal Thyroid NHL Leukemia Hodgkin's
Lymphoma
Corpus Uteri Lung Liver Prostate
3629
2462
1947
1521 1347
1073 923 905 830 725
Breast Thyroid Colon Leukemia Non-Hodgkin…Corpus uteri Lung Liver Kidney Bladder
Source: WHO, Saudi Cancer Registry
Figure 6: Saudi Arabia Cancer Type Patients, 2016 and 2018

19. Copyright 2020. Reproduction is forbidden unless authorized. All rights reserved. 19
Saudi Arabia Tumor Marker Market Outlook, By Revenues
Serial Number List of institutions Funding Cancer Research
1. King Hussein Cancer Center, Saudi Arabia
2. Government of Saudi Arabia, Saudi Arabia
3. King Abdulaziz City for Science and Technology - KACST, Saudi Arabia
4. Ministryof Health of Saudi Arabia, Saudi Arabia
5. Arab Gulf Program For Development, Saudi Arabia
6. Islamic Development Bank, Saudi Arabia
7. Prince Mohammed bin Salman bin Abdulaziz Foundation - MiSK, Saudi Arabia
8. Saudi Cancer Society, Saudi Arabia
9. Zahra Breast Cancer Association, Saudi Arabia
10. Imam Abdulrahman Bin Faisal University, Saudi Arabia
11. King Abdulaziz University,Saudi Arabia
12. King Abdullah Medical City - Oncology Center, Saudi Arabia
13. King Abdullah University of Science and Technology, Saudi Arabia
14. King Khalid University, Saudi Arabia
15. King Saud University, Saudi Arabia
16. Sheikh Mohammed Hussien Al-Amoudi Center of Excellence in Breast Cancer, Saudi Arabia
Source: International Agency for Research on Cancer, WHO
Table 1: Saudi Arabia Cancer Research Funding Institutions, Serial Number, List of the Institutions

20. Copyright 2020. Reproduction is forbidden unless authorized. All rights reserved. 20
Saudi Arabia Tumor Marker Market Outlook, By Application
Figure 7: Saudi Arabia Tumor Marker Market Revenue Share (%), By Application, 2019 & 2025F
• Tumor markers are used for detection, diagnosis and screening of particular type of cancer. A new tumor marker added is the IQ-motif-
containing GTPase-activating protein (IQGAP) family comprises three members, IQGAP1, IQGAP2 and IQGAP3. Emerging cancer types in
Saudi Arabia are breast, thyroid, colorectal and leukemia cancer which uses the different types of tumor markers to diagnose the stage and
the treatment required for the patient.
Cancer Antigen 19-9:
• Cancer Antigen 19-9 is used for the pancreatic cancer and colorectal cancer for in addition to other tests and examinations to diagnose and
monitor the disease. Total number of pancreatic cancer patients in Saudi Arabia estimated to be around 537 as compared to 151 cases in
2025F
Cancer Antigen 19-9
Alpha-fetoprotein
Beta 2 Microglobulin (B2M)
Cancer Antigen 125
Prostate Specific Antigen
Cancer Antigen 15-3 & CA 27-29
Tyroid Transcription factor-1
Crcinoembryonic antigen
Others
2019
Source: MarkNtel Advisors

21. Copyright 2020. Reproduction is forbidden unless authorized. All rights reserved. 21
Saudi Arabia Tumor Marker Market Revenue Share, By Form
Figure 8: Saudi Arabia Tumor Marker Market Revenue Share (%), By Form, 2019 & 2025F
Ovarian:
• Rising prevalence of ovarian cancer and snowballing emphasis on early diagnosis & treatment are anticipated to propel market growth.
Factors such as an increase in number of initiatives by governments and a rise in funding for ovarian cancer research are expected to drive
the market.
 For instance, the Ovarian Cancer Research Alliance (OCRA), a not-for-profit organization, is focused on the R&D of ovarian cancer. It
sponsors several research programs pertaining to the diagnosis & treatment of this disease. Approximately, 70 to 80% of patients
are diagnosed in the advanced stage, thereby significantly reducing treatment options and survival rates, according to OCRA.
Source: MarkNtel Advisors
Ovarian
Leukemia
Prostate
Thyroid
Breast
Colorectal
Lung
Others
2025F2019

22. Copyright 2020. Reproduction is forbidden unless authorized. All rights reserved. 22
Saudi Arabia Tumor Marker Market Revenue Share, By Class
Figure 9: Saudi Arabia Market Revenue Share (%), By Form, 2019 & 2025F
Source: MarkNtel Advisors
2019:
USD X Million
Diagnosis
ScreeningResponse to
Therapy
2019 2025
X% X%
2019 2025
X% X%
2019 2025
X% X%
Others: Medical Lab, etc.
Diagnosis:
• Increasing need to detect small tumors to allow early
diagnosis or help in screening is one of the prime
reason for the growing market share for Diagnosis
segment. They are present in higher quantity in
cancer tissue or in blood from cancer patients more
than in the blood of normal subjects. Moreover, the
availability of markers for specific to single tumor
and different tumors of the same tissue type is
adding pace to the growth in the diagnosis segment.
With the magnifying number of cancer cases in the
country, the demand for markers or proteins is
witnessing an upsurge. The demand for diagnosis
would further grow in coming years as the number
of breast cancer and lung cancer cases are
emanating at a sturdy pace.
Screening:
• The increasing demand for screening of several kind

23. Copyright 2020. Reproduction is forbidden unless authorized. All rights reserved. 23
Saudi Arabia Tumor Marker Market Revenue Share, By Region
Figure 10: Saudi Arabia Tumor Marker Market Revenue Share (%), By Region, 2019 & 2025F
North
 2019: X.X%
 2025F: X.X%
South
 2019: X.X%
 2025F: X.X%
West
 2019: X.X%
 2025F: X.X%
East
 2019: X.X%
 2025F: X.X%
Central
 2019: X.X%
 2025F: X.X%
Source: MarkNtel Advisors

24. Copyright 2020. Reproduction is forbidden unless authorized. All rights reserved. 24
+1 (613) 707-5086
sales@marknteladvisors.com